MedTrace Logo

Evaluation of 11 C-Choline PET-CT for Detection of Hepatocellular Carcinoma

NCT01377220 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2011-06-21

No results posted yet for this study

Summary

Hepatocellular carcinoma (HCC)is the most frequent primitive tumour of the liver.

Recently, several research studies reported that 11C-choline PET has shown a high detection rate of well differentiated HCC, which is an early stage of primary liver cancer. The aim of this study was to prospectively evaluate the diagnostic accuracy of 11C-choline PET-CT to detect HCC in cirrhotic or non cirrhotic patients.

Conditions

Interventions

DRUG

11C-Choline

11C-Choline : 6MBq/kg on direct intravenous on one minute.

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    collaborator OTHER

  • Commissariat A L'energie Atomique

    lead OTHER_GOV

Principal Investigators

  • Maria-Angéla M-A CASTILLA-LIEVRE, MD · Hôpital Antoine Béclère 92140 CLAMART-FRANCE

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2013-06-30
Completion
2014-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01377220 on ClinicalTrials.gov